Mustang Bio, Inc. (NASDAQ:MBIO)
| Market Cap | 3.31M-74.8% |
| Revenue (ttm) | 0 |
| Net Income | -3.03M+7.4% |
| EPS | -0.45+65.2% |
| Shares Out | 7.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,547.134 |
| Open | 0.44 |
| Previous Close | 0.45 |
| Day's Range | 0.43 - 0.44 |
| 52-Week Range | 0.43 - 1.85 |
| Beta | 2.09 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 18, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About MBIO
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$MBIO stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in MBIO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MBIO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MBIO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MBIO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MBIO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MBIO
| ETF | Est. Holding Size |
|---|---|
| PQSGPGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF | $25.82K |
| VXFVanguard Extended Market ETF | $13.82K |
Estimated from each fund’s disclosed top holdings × AUM
MBIO Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MBIO’s recent data — informational, not investment advice